News Details

allosteric modulators for human health

stock datapress releasescorporate eventsdownloads
Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor

Partnership to demonstrate the potential to accelerate the development of allosteric modulator-based therapeutics against GPCRs by integrating proprietary functional and structural biology approaches

 

Geneva, Switzerland, 4 March 2013 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, and Viva Biotech Ltd., a leading company in structure-based drug discovery based in Shanghai, China, today announced they have entered into a partnership to accelerate the advancement of oral small molecule adenosine 2A receptor (A2AR) positive allosteric modulators (PAMs) by leveraging the relative expertise of each company.  The A2AR natural ligand, extracellular adenosine, is locally produced at the sites of inflammation and has been characterized for decades as a “brake for inflammation.”  An oral small molecule compound targeting A2AR activation, which selectively enhances the effect of high adenosine concentration only within inflamed tissues and not in other tissues, may have a profound therapeutic effect in any number of inflammatory-based diseases including rare diseases such as sickle cell and Huntington’s diseases.

“We are delighted to initiate this collaboration with Viva Biotech, a world leader in structural biology of GPCRs,” said Graham Dixon, Chief Scientific Officer at Addex Therapeutics.  “Structural biology is a key complement to our proprietary allosteric modulation capability and increases the chances of us successfully developing novel, allosteric modulators for membrane-associated receptors.  The combination of our industry leading allosteric modulator drug discovery platform with Viva’s cutting-edge structural biology expertise is expected to facilitate the development of a selective and potent oral small molecule for the activation of A2AR, a compelling new mechanism of action to address multiple inflammatory diseases, including certain rare disease indications with significant unmet medical needs.”

Under the terms of the agreement, Viva Biotech will provide a fully-integrated structural biology discovery service to Addex to deliver high resolution crystal structures of A2AR in complex with positive allosteric modulators (PAMs) that were identified using Addex proprietary HTS technologies. Based on this structural information, Addex scientists will then be able to rationally develop novel A2AR PAMs in a structure-guided lead optimization program. To date, Addex’ A2AR PAMs constitute the first examples of chemically tractable, selective, oral small molecule compounds with functional activity on this important GPCR target.

“We are very pleased to be collaborating with Addex on this important program,” said Cheney Mao, Chief Executive Officer of Viva Biotech.  “Viva works with our collaborators to advance novel drug targets from the ideas to identifying novel drug candidates to the clinics, utilizing our broad experience in drug discovery and deep expertise in G2P, G2S, GPCRs and SBDD/FBDD.  With Addex, Viva brings unique structural biology expertise and capability to the partnership.  We believe the combination of our capability with Addex’ state-of-the-art allosteric modulator platform will accelerate the delivery of a clinical candidate against this important GPCR drug target.”

About Addex’ novel A2AR PAMs

Addex has developed proprietary HTS technologies specifically designed to respond to the challenges of detecting and optimizing allosteric modulator drugs. Using this technology, Addex has been able to identify structurally-independent novel chemical series with drug-like properties and with functional activity at the human A2AR in recombinant cell lines as well as in a cell line endogenously expressing A2AR. In addition, these compounds have been shown to be active in industry-standard assays (such as cAMP HTRF and GTP-gamma-S assays) and do not compete with radioactive orthosteric ligand binding, exemplifying their allosteric mechanism of action.  These novel compounds are selective for A2AR, do not demonstrate any agonist activity and are only active in the presence of adenosine binding to the active site of A2AR. 

About allosteric modulators

Allosteric modulators are an emerging class of orally available small molecule therapeutic agents that may offer a competitive advantage over classical drugs. This potential stems from their ability to offer greater selectivity and better modulatory control at disease mediating receptors. Most marketed drugs bind receptors where the body’s own natural molecular activators (i.e. endogenous ligands) bind, specifically to a key part of each receptor called the “active site”. In short, most drugs must out-compete endogenous ligands in order to bind to the active site. By contrast, allosteric modulators are non-competitive because they bind receptors at a different site and modify receptor function in the presence of endogenous ligand binding to the active site. Because of this, allosteric modulators are not limited to simply turning a receptor “on” or “off”, the way most conventional drugs are designed. Instead, allosteric modulators act more like a dimmer switch, offering control over the intensity of activation or deactivation, while allowing the body to retain its natural control over initiating receptor activation. One of the most attractive features of receptor activation via allosteric modulation is that these positive allosteric modulators (PAMs) activate the receptor only in the presence of the natural ligand binding to the target receptor.  In the absence of natural ligand these PAMs do not activate the receptor.  This provides an elegant regulate the receptor activation that could translate into the development of a safer therapeutic.

Pharmacological advantages of PAMs for the activation of A2AR

Beside immune cells, A2AR engagement modulates the activity of numerous cell types, including various neuronal populations, platelets, smooth muscle and endothelial cells. Thus, systemic engagement of A2AR with orthosteric agonists, directed at the adenosine binding site, is known to affect several tissues and trigger a wide range of side effects such as hypotension and tachycardia. Extracellular adenosine is locally produced within inflamed or hypoxic tissues and is highly unstable in plasma. Therefore, in the course of inflammatory reactions, ligand availability regulates adenosine receptors engagement both in space and time. Because it preserves the natural spatial and temporal controls over A2AR engagement, positive allosteric modulation provides a uniquely suited therapeutic approach to address the potential of A2AR activation in chronic inflammatory diseases. By enhancing the effect of high adenosine concentration within inflamed tissues, A2AR PAM would avoid side effects that relate to ectopic or systemic triggering of A2AR and could offer a greater selectivity over other adenosine receptors. In particular, A2AR PAMs are expected to show reduced impact on hypotension and tachycardia than straight agonists.

About A2AR in inflammatory conditions

Adenosine 2A receptor (A2AR or ADORA2A), a Family A class of G-protein coupled receptor (GPCR) can, among other things, negatively regulate over reactive immune cells, thereby protecting tissues from collateral inflammatory damage, The A2AR’s natural ligand, extracellular adenosine, is locally produced at the sites of inflammation and has been characterized for decades as a “brake for inflammation”, exerting a retro-control over inflammation. Several lines of evidence point to a broad anti-inflammatory role of A2AR in preclinical animal models. In leukocytes, A2AR is the most abundantly expressed adenosine receptor and activating this receptor affects a range of cellular functions across different immune cell types including macrophage cytokines production, neutrophil migration, or T-lymphocyte activation. A2AR selective agonists show anti-inflammatory activity and reduce tissue damage in vivo. Conversely, A2AR selective antagonists compromise regulatory T cells function and prolong inflammation following induction of an inflammatory response. Similarly, A2AR-deficient animals show enhanced and prolonged inflammatory responses.

Several marketed anti-inflammatory drugs, including methotrexate and sulfasalazine, mediate some of their anti-inflammatory effects through a mechanism that promotes adenosine release and activation of A2AR. However, these drugs are non-specific and associated with significant side effects.  In addition, there is marked variability in the degree of efficacy and side effects observed with these current drugs in the clinic.  There is a need for products that are selective, safe and truly disease-modifying. Therefore, an oral small molecule drug targeting A2AR with a new mechanism of action such as an A2AR PAM that is active only at the sites of inflammation, lacks any agonist activity and preferably is peripheral, could revolutionize and offer an attractive alternative to the existing therapeutic arsenal for the treatment of a number of inflammatory conditions, such as rheumatoid arthritis (RA), Crohn’s disease and psoriasis, as well as certain rare diseases such as , sickle cell and Huntington’s disease.

About Viva Biotech

Viva Biotech (www.vivabiotech.com) is privately owned and financed by leading investors in the United States. It is a well-established contract research organization that provides preclinical drug discovery research services to the pharmaceutical industry worldwide. The core capabilities of the company includes its leading expertise in protein crystallography and structure based drug design, a MS based screening technology with a proprietary fragment library, GPCR target preparation and crystallization, monoclonal antibody lead generation and other preclinical drug discovery research capabilities such as DMPK, animal disease models for CNS and oncology. For additional information on Viva Biotech, please contact Dr. Zengquan Wang at: Zengquan.wang@vivabiotech.com.

About Addex Therapeutics

Addex Therapeutics (www.addextherapeutics.com) is a development stage company focused on advancing innovative oral small molecules against rare diseases utilizing its pioneering allosteric modulation-based drug discovery platform. The Company's two lead products are being investigated in Phase 2 clinical testing: dipraglurant (ADX48621, an mGlu5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID) and rare forms of dystonia; and ADX71149 (mGlu2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc. to treat both schizophrenia and anxiety as seen in patients suffering from major depressive disorder. Addex is also advancing several preclinical programs including: GABA-BR positive allosteric modulator (PAM) for Charcot-Marie-Tooth (type 1a) disease, spasticity in patients with multiple sclerosis (MS), pain, overactive bladder and other disorders; and mGlu4 PAM for MS, Parkinson's disease, anxiety and other diseases. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. The Company uses its proprietary discovery platform to target receptors and other proteins that are recognized as essential for the therapeutic modulation of important diseases with unmet medical needs.

Tim Dyer
Chief Financial Officer
Addex Therapeutics
+41 22 884 15 61
PR(at)addextherapeutics.com

Disclaimer: The foregoing release may contain forward-looking statements that can be identified by terminology such as "not approvable", "continue", "believes", "believe", "will", "remained open to exploring", "would", "could", or similar expressions, or by express or implied discussions regarding Addex Therapeutics, formerly known as, Addex Pharmaceuticals, its business, the potential approval of its products by regulatory authorities, or regarding potential future revenues from such products. Such forward-looking statements reflect the current views of Addex Therapeutics regarding future events, future economic performance or prospects, and, by their very nature, involve inherent risks and uncertainties, both general and specific, whether known or unknown, and/or any other factor that may materially differ from the plans, objectives, expectations, estimates and intentions expressed or implied in such forward-looking statements. Such may in particular cause actual results with allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutic targets to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutics targets will be approved for sale in any market or by any regulatory authority. Nor can there be any guarantee that allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutic targets will achieve any particular levels of revenue (if any) in the future. In particular, management's expectations regarding allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutic targets could be affected by, among other things, unexpected actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Addex Therapeutics is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except as may be required by applicable laws.

 

PDF version

Addex ADX71441 Demonstrates Preclinical Analgesic Effects

Support Potential of ADX71441 to treat Irritable Bowel Syndrome, Interstitial Cystitis and Painful Bladder Syndrome

Geneva, Switzerland, 9...

Addex ADX71441 Preclinical Results for Treatment of Alcohol Use Disorder Published in Journal of Psychopharmacology

 

Study Conducted in Collaboration with National Institute on Alcohol Abuse and Alcoholism

Geneva,...

Addex Therapeutics Provides Corporate Update and Reports 2016 Financial Results

Geneva, Switzerland, 5 April 2017 – Addex Therapeutics (SIX: ADXN) today provided a corporate update and reported full-year 2016 financial results.

Addex Raises CHF3.0 million Through Private Placement of Treasury Shares and Extends Cash Runway Through 2018


Geneva, Switzerland, 28 February 2017 – Addex Therapeutics (SIX: ADXN) announced today that it has raised gross proceeds of CHF3.0 million through a private...

Addex’s ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia


Geneva, Switzerland, 27 February 2017 – Addex Therapeutics (SIX: ADXN) announced today the publication of a study demonstrating the anti-epileptic effects of...

Addex’s Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases


Geneva, Switzerland, 6 February 2017 – Addex Therapeutics (SIX: ADXN) announced today the publication of a review summarizing the current status of allosteric...

Addex Awarded $835,000 Grant from Michael J. Fox Foundation to Advance TrkB PAMs for the Treatment of Parkinson’s Disease


Geneva, Switzerland, 31 January 2017
– Addex Therapeutics (SIX: ADXN) announced today that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has...

Addex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain

 

Geneva, Switzerland, 9 January 2017 – Addex Therapeutics (SIX: ADXN), announced today that ADX71441, a positive allosteric...

Addex ADX71441 Pharmacological Profile Published in Neuropharmacology

 

Geneva, Switzerland, 13 December 2016 – Addex Therapeutics (SIX: ADXN), announced today that the pharmacological profile of...

Addex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer

Dr Mills adds extensive expertise in Parkinson’s disease drug development and commercialization

Geneva, Switzerland, 28...

Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia


Company Expects to Initiate Study in Fourth Quarter of 2016

Trial Design Developed in Collaboration with Emory...

Addex Initiates New Study in Collaboration with US National Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of Cocaine Addiction

 

Geneva, Switzerland, 11 October 2016 – Addex Therapeutics (SIX: ADXN) announced today it has initiated a new study with...

Addex Therapeutics Reports First Half 2016 Operating Highlights and Financial Results

Geneva, Switzerland, 30 September 2016 – Addex Therapeutics (SIX: ADXN) announced today its first half 2016 operating highlights and financial results.

<span style="font-weight:...

Addex Collaborators Published New Data Supporting the Role of Negative Allosteric Modulators of Follicle Stimulating Hormone and Luteinizing Hormone Receptors in Reproductive Health

 

Geneva, Switzerland, 20 September 2016 – Addex Therapeutics (SIX: ADXN) announced today the publication of new scientific...

Addex ADX71441 Demonstrates Positive Results in Highly Translational Preclinical Model of Spasticity.


Geneva, Switzerland, 27 July 2016 – Addex Therapeutics (SIX: ADXN) announced today that ADX71441, a positive allosteric modulator (PAM) of the GABAB receptor...

LifeSci Capital Issues Equity Research Report on Addex Therapeutics

 

Geneva, Switzerland, 20 July 2016 – Addex Therapeutics (SIX: ADXN), announced today that the independent life science research...

Addex Shareholders Approved all Board Proposals at 2016 Annual General Meeting


Geneva, Switzerland, 24 June 2016 – Addex Therapeutics (SIX: ADXN), announced today that its shareholders approved all the proposals of the board of directors...

Addex ADX71441 Demonstrates Positive Results in Non-Human Primate Model of Cocaine Addiction


Geneva, Switzerland, 9 June 2016 – Addex Therapeutics (SIX: ADXN), announced today positive results with ADX71441, a GABAB receptor positive allosteric...

Van Leeuwenhoeck Issues Research Note on Addex Therapeutics


Geneva, Switzerland, 8 June 2016 – Addex Therapeutics (SIX: ADXN), announced today that the independent life science research company Van Leeuwenhoeck has...

Addex Annual General Meeting Scheduled for 23 June 2016


Geneva, Switzerland  2 June 2016 – Addex Therapeutics (SIX: ADXN), announced today that its Annual General Meeting will take place on Thursday, 23 June 2016, at 11:00am at the...

Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society


Geneva, Switzerland, 2 June 2016 – Addex Therapeutics (SIX: ADXN) announced today that results from its Phase 2 clinical study of dipraglurant in...

Addex Increases Issued Share Capital and Creates Treasury Shares

 

Geneva, Switzerland, 30 May 2016 – Addex Therapeutics (SIX: ADXN) announced today that it has increased its capital from...

Addex Therapeutics Reports 2015 Financial Results

Geneva, Switzerland, 29 April 2016 – Addex Therapeutics (SIX: ADXN) announced today 2015 financial results.


2015 Financial Highlights...

Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

 

Geneva, Switzerland, 11 April 2016 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development,...

Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers


Geneva, Switzerland, 15 March 2016 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development,...

Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept

 

Additional analysis underlines the potential significant therapeutic benefit of dipraglurant to patients with Parkinson’s disease....

Addex’ Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease


FDA Orphan Drug Status Validates the Potential Therapeutic Use of Dipraglurant in this Rare Disease

Geneva,...

Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial


Geneva, Switzerland, 17 December 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex and University of Geneva Collaborators Awarded Swiss Grant to Profile Addex TrkB Allosteric Modulators as Neuroprotective Agents


Geneva, Switzerland, 15 December 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis


Geneva, Switzerland, December 9, 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex Moves R&D Operations to Geneva’s Campus Biotech


Geneva, Switzerland, December 7, 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex ADX71441 Included in the NINDS Anticonvulsant Screening Program


Geneva, Switzerland, 25 November 2015
– Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 and mGluR4 Allosteric Modulators for Neurodegenerative and Psychiatric Diseases


Geneva, Switzerland, 23 November 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

ValuationLAB Issues Research Report on Addex Therapeutics with Share Price Estimate of CHF5.2 per Share


Geneva, Switzerland, 19 November 2015
– Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex’ ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder


Successful collaboration with the US National Institute for Alcohol Abuse and Alcoholism

Geneva, Switzerland, 13 October 2015 – Addex Therapeutics...

Addex Therapeutics Reports First Half 2015 Financial Results

Geneva, Switzerland, 30 September 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development,...

Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy


Geneva, Switzerland, 23 September 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Pierre Fabre Pharmaceuticals and Addex Therapeutics Sign Early-Stage Agreement in the Central Nervous System (CNS) Field


  • Addex Grants Option to License mGlu3 Receptor Program to Pierre Fabre Pharmaceuticals
  • Pierre Fabre Pharmaceuticals will conduct chemistry, pharmacology and ADME*

<p...

Alpha Deal Group Initiates Independent Research Coverage on Addex Therapeutics


Geneva, Switzerland, 17 August 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development,...

Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson’s Disease

 

Geneva, Switzerland 14 August 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

valuationLAB Issues Research Report on Addex Therapeutics


Geneva, Switzerland, 5 August 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development,...

Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation

 

Geneva, Switzerland, 22 July 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based...

Addex Shareholders Appoint Raymond Hill and Tim Dyer to the Board of Directors and approve all Board Proposals at Annual General Meeting

Geneva, Switzerland, 12 June 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced...

Addex Identifies New Potential Use of mGlu7 receptor NAMs to Treat Stress-Induced Visceral Pain

 

Geneva, Switzerland 3 June 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and...

Addex and Prof. Pisani Present Dipraglurant data in Rare Inherited Forms of Dystonia

 

5th Biennial Workshop on Dystonia “Controversies in Dystonia and Parkinsonism” Rome, 29-30 May 2015

Geneva, Switzerland 29 May 2015 – Addex Therapeutics (SIX: ADXN), a leading company...

Addex Enters Collaboration with Prof. Pisani to Explore the Therapeutic use of Dipraglurant in the Treatment of Rare Inherited Forms of Dystonia

 

Geneva, Switzerland 7 May 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today entering a...

Addex Raises CHF2.8 million in a Private Placement and Extends Cash Runway Through 2017

 

Geneva, Switzerland, 9 March 2015 – Addex Therapeutics (SIX: ADXN) announced today that it has raised gross proceeds of CHF2.8 million in a private placement of new issued registered...

Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation

Geneva, Switzerland, 23 February 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug...

Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death

 

Geneva, Switzerland, 19 February 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that...

Addex Completes 2014 with Strong Cash Position and Provides 2015 Strategic Update

 

Geneva, Switzerland, 9 January 2015 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today:

Financial Update<br...

Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder


Geneva, Switzerland, 7 January 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today...

Addex Amends mGlu2PAM Collaboration Agreement and Receives USD757,000

 

Geneva, Switzerland, 17 December 2014 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has received USD757,000...

Addex and the Charcot-Marie-Tooth Association enter collaboration to advance ADX71441 in Charcot-Marie-Tooth 1A disorder

 

Geneva, Switzerland, 21 October 2014 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today entering a...

Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction


ADX71441 reversed somatic signs of withdrawal in nicotine-dependent mice and reversed hyperalgesia, further supporting the use of GABA-B activation as a strategy to achieve smoking cessation

Geneva, Switzerland, 10...

Addex Shareholders Approve All Board Proposals at Annual General Meeting

 

Geneva, Switzerland, 30 June 2014 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved all...

Addex Therapeutics Publishes Annual General Meeting Agenda

Geneva, Switzerland, 12 June 2014 - Addex Therapeutics (SIX:...

Addex Therapeutics Publishes Annual Report 2013

 

Geneva, Switzerland, 30 May 2014 - Addex Therapeutics (SIX: ADXN) announced today the publication of its Annual Report 2013 in accordance with the notice given in the press release of 30 April...

Addex Therapeutics Reports 2013 Financial Results

 

2013 Financial Highlights

  • Significant reduction in 2013 cash utilization of CHF12.3 million, significantly below guidance of CHF15 million, CHF1.6 million used in second half of 2013...

Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms

 

Geneva, Switzerland, 7 February 2014 - (SIX:ADXN), Addex Therapeutics, a leading company pioneering allosteric modulation-based drug discovery and development, announced today top-line data from a Phase 2a...

Addex and NIDA enter collaboration to advance ADX71441 & ADX88178 in drug abuse and addiction

 

Geneva, Switzerland, 4 November 2013 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today entering a collaboration with the...

Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression

On track to report top line results end of Q1 2014

Geneva, Switzerland, 29 October 2013 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development...

Addex ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease

Geneva, Switzerland, 3 October 2013 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that ADX71441 dose...

Addex Therapeutics First Half 2013 Financial Results

 

Geneva, Switzerland, 17 September 2013 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today its first...

Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1

 

Geneva, Switzerland, 4 September 2013 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today additional...

Addex Therapeutics raises CHF3.2 million in a Private Placement to International Institutional Investors

Cash runway extended to end of 2014

Geneva, Switzerland, 9 August 2013 – Addex Therapeutics (SIX: ADXN) announced today that it has raised gross proceeds of CHF3.2 million (US$3.5 million) in a private placement...

Addex Completes Restructuring to Focus on Capturing Potential Upside from its Partnered Asset and CEO Steps Down

                             
Geneva, Switzerland, 31 May...

Addex Announces Steps to Capture Potential Upside from its Partnered Asset and Preserve Value for Shareholders


Company intends to restructure the organization and monetize its pipeline and platform assets

Geneva, Switzerland, 28 May 2013 – Addex Therapeutics (SIX: ADXN), announced today that it...

Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441

  • ADX71441 produced dose-dependent changes on growth hormone (GH) plasma concentrations in a preclinical model
  • The data confirms the role of gamma-aminobutyric acid (GABA) in modulating GH plasma concentrations...

Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study

 

• Dose-dependent receptor occupancy correlates with plasma exposure and links to efficacy in non-human primate model of Parkinson’s Disease levodopa-induced dyskinesia
• Data reinforces Phase 2a pharmacological...

Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role

 

Geneva, Switzerland, 30 April 2013 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced that Tim Dyer, Co-Founder and Chief...

Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence


• Data reinforces broad therapeutic potential of ADX71441, an oral GABAB receptor Positive Allosteric Modulator
• Recent approval of Clinical Trial Application (CTA)  to initiate a Phase 1, first–in-man,...

Addex Receives Approval to Initiate a Phase 1, First–In-Man, Clinical Study for ADX71441


ADX71441, a novel oral small molecule GABA-B receptor positive allosteric modulator, on track to initiate clinical testing in first half of 2013 and to deliver top-line safety, PK and biomarker data by year...

Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant

Dipraglurant, an mGlu5 negative allosteric modulator, in clinical development for levodopa-induced dyskinesia as well as certain rare dystonias

Geneva, Switzerland, 22 April 2013 – Addex Therapeutics (SIX:ADXN),...

Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)

Dipraglurant, an mGlu5 negative allosteric modulator, currently in Phase 2 studies for levodopa-induced dyskinesia is on track for start of Phase 2 studies in rare dystonias in the first half of...

Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN)

$1 MM grant by The Michael J. Fox Foundation to be used to help fund further human clinical testing of dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia

Geneva,...

Addex Shareholders Approve All Board Proposals at Annual General Meeting

Geneva, Switzerland, 20 March 2013 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its...

Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research

Grant to be used to help fund further human clinical testing of dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia

<link...

Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor

Partnership to demonstrate the potential to accelerate the development of allosteric modulator-based therapeutics against GPCRs by integrating proprietary functional and structural biology...

Addex to Focus Resources on Clinical Pipeline

 

2013 Value Drivers:

• Initiate Phase 2 clinical testing of dipraglurant (mGlu5 NAM) in a rare disease indication
• Submit Orphan Drug Application in U.S. and Europe for dipraglurant<br...

Addex Dipraglurant Reduces Motor Abnormalities in a Preclinical Model Relevant for Several Rare types of Dystonia


Dipraglurant, a novel oral small molecule negative allosteric modulator of mGlu5 receptor, on track for Phase 2 clinical testing in the second half of 2013

 

Addex Announces Issuance of a Broad US Composition of Matter Patent for ADX71441

ADX71441, a novel oral small molecule positive allosteric modulator of GABA-B receptor, on track for Phase 1 clinical testing in the first half of 2013

Allostery: Key to addressing important unmet needs in CNS diseases

Addex'high throughput allosteric drug discovery platform is paving the way for a new approach to cracking "undruggable" therapeutic targets.

Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Alcohol Binge Drinking

- Data reinforces broad therapeutic potential of oral ADX71441 

-

Dyskinesia: Hope on the Horizon

YouTube

Addex and Collaborators Awarded Swiss CTI Grant to Develop Allosteric Modulators for Neurodegenerative and Psychiatric Diseases


Grant to Further Characterize Allosteric Modulators Against mGluR4 and mGluR7
Geneva, Switzerland, 2 October 2012

Addex...

Addex mGluR4 Allosteric Modulator Effective in Multiple Sclerosis Model

A Novel Oral Small Molecule Approach for the Treatment of Multiple Sclerosis
Geneva, Switzerland, 24 September 2012 – Addex Therapeutics (SIX:ADXN), a leading company pioneering...

Soutien américain au biotech à Genève

ADDEX.Le titre a bénéficié d'un regain d'intérêt des investisseurs outre-Atlantique.
La direction plaide encore la sous-évalutation.

Addex Partner Doses First Patient in Phase 2 Clinical Study of ADX71149 for the Treatment of Major Depressive Disorder Patients with Anxiety Symptoms

Geneva, Switzerland, 17 September 2012 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug...

Addex Therapeutics First Half 2012 Financial results

Geneva, Switzerland, 22 August 2012 – Addex Therapeutics...

Positive Early Results for Addex Parkinson's Drug Dipraglurant Spur Hopes for Deal


In a small, short Phase IIa study, an oral inhibitor of mGluR5 proved effective at reducing dyskinesia caused by levodopa.

Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson’s Disease Pre-Clinical Models


- Seminal Research Provides Greater Insight into the Role of Selective mGluR4 Modulation on Motor Symptoms